π Lilly crushes expectations with GLP-1 drug sales
Lilly surpassed market estimates due to strong, resilient demand for its injectable GLP-1 drugs. The company reported these impressive results in the US market. Specifically, Q4 revenue reached $15.1 billion, a significant jump from previous quarters. This performance further widens the competitive gap between Lilly and its rival, Novo Nordisk. Analysts expect continued growth driven by the sustained popularity of these diabetes and weight-loss treatments.